1. Home
  2. CCEL vs HBIO Comparison

CCEL vs HBIO Comparison

Compare CCEL & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cryo-Cell International Inc.

CCEL

Cryo-Cell International Inc.

HOLD

Current Price

$3.50

Market Cap

29.2M

Sector

Health Care

ML Signal

HOLD

Logo Harvard Bioscience Inc.

HBIO

Harvard Bioscience Inc.

HOLD

Current Price

$6.20

Market Cap

24.9M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCEL
HBIO
Founded
1989
1901
Country
United States
United States
Employees
N/A
N/A
Industry
Managed Health Care
Biotechnology: Laboratory Analytical Instruments
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
29.2M
24.9M
IPO Year
2022
2000

Fundamental Metrics

Financial Performance
Metric
CCEL
HBIO
Price
$3.50
$6.20
Analyst Decision
Hold
Buy
Analyst Count
1
2
Target Price
N/A
$18.00
AVG Volume (30 Days)
6.3K
26.1K
Earning Date
04-14-2026
05-12-2026
Dividend Yield
4.26%
N/A
EPS Growth
N/A
N/A
EPS
0.01
N/A
Revenue
$25,384,279.00
$116,176,000.00
Revenue This Year
N/A
$4.77
Revenue Next Year
N/A
$8.55
P/E Ratio
$350.00
N/A
Revenue Growth
9.76
N/A
52 Week Low
$2.72
$0.38
52 Week High
$5.52
$7.50

Technical Indicators

Market Signals
Indicator
CCEL
HBIO
Relative Strength Index (RSI) 49.70 53.07
Support Level $3.18 $6.05
Resistance Level $3.57 $7.00
Average True Range (ATR) 0.21 0.44
MACD -0.01 0.05
Stochastic Oscillator 65.43 67.58

Price Performance

Historical Comparison
CCEL
HBIO

About CCEL Cryo-Cell International Inc.

Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.

About HBIO Harvard Bioscience Inc.

Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.

Share on Social Networks: